[Click eStock] "Biol, Clear Outlook for Second Half Performance"

NH Investment & Securities forecasted on the 13th that Biol's performance will improve in the second half of this year.

Biol recorded sales of 15.2 billion KRW and an operating profit of 9.7 billion KRW in the second quarter. These figures represent increases of 43.5% and 70.4%, respectively, compared to the same period last year.

Shim Eui-seop, a researcher at NH Investment & Securities, explained, "Income from technology transfer related to the ITC lawsuit was reflected at 1.4 billion KRW in the first quarter and approximately 3.7 billion KRW in the second quarter," adding, "Sales of consumables increased by 66.2% due to the rise in procedures following the expansion of equipment distribution."

He added, "The achievements in newly entered markets such as China and Brazil are also expanding and will contribute to the company's overall performance," and "The new product 'Cellinew,' launched in June, and 'Duotight,' scheduled for release in the second half of the year, will also contribute from a mid- to long-term perspective."

Researcher Shim stated, "The first ITC ruling has been postponed to September 9," and expressed, "Although it is difficult to predict the outcome, a victory would not only have financial effects but also serve as an opportunity to strengthen Biol's position in the Needle RF market."

He further advised, "It is recommended to approach with a focus on Biol's performance growth from a mid- to long-term perspective."